AAN 2026: Tavapadon post-hoc analysis strengthens its D1/D5 agonist pitch
On 21 April, at the 2026 American Academy of Neurology (AAN) meeting, AbbVie presented new results from its post-hoc analysis…
Analyst Comment
AAN 2026: Head-to-head trial shows superiority of Qulipta for migraine prevention
Biogen seeks Darzalex rivalry in China for multiple myeloma with felzartamab deal
ESCMID Global 2026: Zelicapavir demonstrates benefits for high-risk adults with RSV
Pharma Meets AI Conference 2026: Key barriers to scaling AI in drug development
ESCMID Global 2026: Adibelivir emerges as potential disease-modifying therapy for HSV
Immunotherapy in locally advanced HNSCC: is there still room for new agents?
Beyond GLP-1Rs: emerging targets poised to gain share of obesity market
